Farhaan S Vahidy1, William J Hicks1, Indrani Acosta1, Hen Hallevi1, Hui Peng1, Renganayaki Pandurengan1, Nicole R Gonzales1, Andrew D Barreto1, Sheryl Martin-Schild1, Tzu-Ching Wu1, Mohammad H Rahbar1, Arvind B Bambhroliya1, James C Grotta1, Sean I Savitz2. 1. From the Department of Neurology, Medical School (F.S.V., W.J.H., I.A., H.H., N.R.G., A.D.B., S.M.-S., T.-C.W., A.B.B., J.C.G., S.I.S.), Center for Clinical and Translational Sciences (H.P., R.P., M.H.R.), and Department of Epidemiology, Human Genetic and Environmental Sciences, School of Public Health (M.H.R.), University of Texas Health Science Center at Houston. 2. From the Department of Neurology, Medical School (F.S.V., W.J.H., I.A., H.H., N.R.G., A.D.B., S.M.-S., T.-C.W., A.B.B., J.C.G., S.I.S.), Center for Clinical and Translational Sciences (H.P., R.P., M.H.R.), and Department of Epidemiology, Human Genetic and Environmental Sciences, School of Public Health (M.H.R.), University of Texas Health Science Center at Houston. Sean.I.Savitz@uth.tmc.edu.
Abstract
OBJECTIVE: The purpose of this study was to assess the incidence of deterioration, fluctuation, and associated risk of poor outcome in patients with subcortical stroke (SCS). METHODS: We conducted a prospective observational study, enrolling patients admitted with SCS based on their clinical examination and imaging studies. An NIH Stroke Scale evaluation was performed daily and whenever deterioration in examination was detected. Neurologic deterioration was defined as a motor score increase of at least 1 on the NIH Stroke Scale. Modified Rankin Scale scores at discharge were used to assess outcome. RESULTS: Among 90 enrolled patients, 37 (41%) deteriorated, 75% of them in the first 24 hours after enrollment. Administration of tissue plasminogen activator was significantly associated with deterioration (hazard ratio 2.25; 95% confidence interval [CI]: 1.13-4.49) even after controlling for the association of deterioration with the early poststroke period. Deterioration conferred an increased risk of poor outcome (modified Rankin Scale scores 3-6) at discharge (relative risk: 1.80; 95% CI: 1.71-1.93). Reversion back to predeterioration deficits occurred in 38% of patients, and was associated with reduced risk of poor outcome at discharge (relative risk: 0.12; 95% CI: 0.02-0.83). Treatment with tissue plasminogen activator conferred better chances of spontaneous recovery to predeterioration deficits after initial deterioration (hazard ratio: 4.36; 95% CI: 1.36-14.01). CONCLUSION: More than 40% of patients with SCS deteriorate neurologically. Deterioration tends to occur early after stroke, spontaneously reverses in approximately one-third of cases, and poses an increased risk of poor outcome. Therapies are needed to prevent, arrest, or reverse deterioration in patients with SCS.
OBJECTIVE: The purpose of this study was to assess the incidence of deterioration, fluctuation, and associated risk of poor outcome in patients with subcortical stroke (SCS). METHODS: We conducted a prospective observational study, enrolling patients admitted with SCS based on their clinical examination and imaging studies. An NIH Stroke Scale evaluation was performed daily and whenever deterioration in examination was detected. Neurologic deterioration was defined as a motor score increase of at least 1 on the NIH Stroke Scale. Modified Rankin Scale scores at discharge were used to assess outcome. RESULTS: Among 90 enrolled patients, 37 (41%) deteriorated, 75% of them in the first 24 hours after enrollment. Administration of tissue plasminogen activator was significantly associated with deterioration (hazard ratio 2.25; 95% confidence interval [CI]: 1.13-4.49) even after controlling for the association of deterioration with the early poststroke period. Deterioration conferred an increased risk of poor outcome (modified Rankin Scale scores 3-6) at discharge (relative risk: 1.80; 95% CI: 1.71-1.93). Reversion back to predeterioration deficits occurred in 38% of patients, and was associated with reduced risk of poor outcome at discharge (relative risk: 0.12; 95% CI: 0.02-0.83). Treatment with tissue plasminogen activator conferred better chances of spontaneous recovery to predeterioration deficits after initial deterioration (hazard ratio: 4.36; 95% CI: 1.36-14.01). CONCLUSION: More than 40% of patients with SCS deteriorate neurologically. Deterioration tends to occur early after stroke, spontaneously reverses in approximately one-third of cases, and poses an increased risk of poor outcome. Therapies are needed to prevent, arrest, or reverse deterioration in patients with SCS.
Authors: A V Alexandrov; R A Felberg; A M Demchuk; I Christou; W S Burgin; M Malkoff; A W Wojner; J C Grotta Journal: Stroke Date: 2000-04 Impact factor: 7.914
Authors: Sam Wang; Sung Bae Lee; Carol Pardue; Davinder Ramsingh; Jennifer Waller; Hartmut Gross; Fenwick T Nichols; David C Hess; Robert J Adams Journal: Stroke Date: 2003-09-18 Impact factor: 7.914
Authors: Shadi Yaghi; Sara K Rostanski; Amelia K Boehme; Sheryl Martin-Schild; Alyana Samai; Brian Silver; Christina A Blum; Mahesh V Jayaraman; Matthew S Siket; Muhib Khan; Karen L Furie; Mitchell S V Elkind; Randolph S Marshall; Joshua Z Willey Journal: JAMA Neurol Date: 2016-05-01 Impact factor: 18.302
Authors: Eckhard Schlemm; Thies Ingwersen; Alina Königsberg; Florent Boutitie; Martin Ebinger; Matthias Endres; Jochen B Fiebach; Jens Fiehler; Ivana Galinovic; Robin Lemmens; Keith W Muir; Norbert Nighoghossian; Salvador Pedraza; Josep Puig; Claus Z Simonsen; Vincent Thijs; Anke Wouters; Christian Gerloff; Götz Thomalla; Bastian Cheng Journal: Nat Commun Date: 2021-05-10 Impact factor: 14.919